Program
osivelotor
Also written as “Osivelotor”, “GBT021601” and “PF-07940367”.
In Pfizer's pipeline, HbS polymerization inhibitor
. Its studies are mostly in Anemia, Sickle Cell · Liver Diseases · Renal Insufficiency, led by Pfizer.
Furthest: phase 3, since Jun 21, 20229 company-led studies, 2 open or runningNext primary completion: Feb 8, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 92 open or running | phase 3since Jun 21, 2022 | May 27, 2021 | Feb 8, 2027phase 1 · NCT06507904 |
- Named in Pfizer’s own pipeline as
osivelotor PF-07940367
, phase 3, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 27, 2021First study: phase 1 study in Anemia, Sickle CellFirst studyNCT04983264 · 6 enrolled · United States
- Aug 13, 2021Phase 1 study in Anemia, Sickle CellNCT05036512 · 129 enrolled · United States, Australia
- Jun 21, 2022Phase 3 study in Anemia, Sickle CellNCT05431088 · 389 planned · United States, Brazil, India and more
- Nov 1, 2022Phase 3 study in Anemia, Sickle CellNCT05632354 · 47 enrolled · United States, Nigeria
- Jan 30, 2023Phase 1 study in Anemia, Sickle CellNCT05718687 · 9 enrolled · Netherlands
- May 19, 2023Phase 1 study in Renal InsufficiencyNCT05878704 · 8 enrolled · United States
- Dec 19, 2023Phase 1 study in HealthyNCT06190561 · 40 enrolled · United States
- Mar 25, 2024Phase 1 study in Liver DiseasesNCT06340347 · 8 enrolled · United States
- Jul 12, 2024Phase 1 study in HealthyNCT06507904 · 52 planned · Belgium
Ahead
- Feb 8, 2027Primary completion: phase 1 study in HealthyNCT06507904
- Dec 30, 2030Primary completion: phase 3 study in Anemia, Sickle CellNCT05431088
TargetBeta
“HbS polymerization inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable sickle cell hemoglobin S (HbS) stabilizer and polymerization inhibitor, with potential use in the treatment of sickle cell disease (SCD). Upon oral administration, osivelotor targets and covalently binds to HbS. This increases the affinity of Hb for oxygen and stabilizes it…”NCIt, read by Claude
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06507904Healthy · Belgium | 1 | Recruiting | Feb 8, 2027 | 52 |
| NCT06340347Liver Diseases · United States | 1 | Completed | Sep 18, 2024 | 8 |
| NCT06190561Healthy · United States | 1 | Completed | May 7, 2024 | 40 |
| NCT05878704Renal Insufficiency · United States | 1 | Terminated | Jul 29, 2024 | 8 |
| NCT05718687Anemia, Sickle Cell · Netherlands | 1 | Completed | Aug 10, 2023 | 9 |
| NCT05632354Anemia, Sickle Cell · United States, Nigeria | 3 | Terminated | Feb 13, 2025 | 47 |
| NCT05431088Anemia, Sickle Cell · United States, Brazil, India and more | 3 | Recruiting | Dec 30, 2030 | 389 |
| NCT05036512Anemia, Sickle Cell · United States, Australia | 1 | Completed | Nov 2, 2022 | 129 |
| NCT04983264Anemia, Sickle Cell · United States | 1 | Completed | Dec 6, 2022 | 6 |
How it is read
Names in the registry
- “Osivelotor”, 4 entries
- “GBT021601”, 4 entries
- “PF-07940367”, 2 entries
Conditions, from the studies’ own filings
- Anemia, Sickle Cell, 5 studies
- Liver Diseases, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.